It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Evening light-emitting visual displays may disrupt sleep, suppress melatonin and increase alertness. Here, we control melanopic irradiance independent of display luminance and colour, in 72 healthy males 4 h before habitual bedtime and expose each of them to one of four luminance levels (i.e., dim light, smartphone, tablet or computer screen illuminance) at a low and a high melanopic irradiance setting. Low melanopic light shortens the time to fall asleep, attenuates evening melatonin suppression, reduces morning melatonin, advances evening melatonin onset and decreases alertness compared to high melanopic light. In addition, we observe dose-dependent increases in sleep latency, reductions in melatonin concentration and delays in melatonin onset as a function of melanopic irradiance—not so for subjective alertness. We identify melanopic irradiance as an appropriate parameter to mitigate the unwanted effects of screen use at night. Our results may help the many people who sit in front of screens in the evening or at night to fall asleep faster, feel sleepier, and have a more stable melatonin phase by spectrally tuning the visual display light without compromising the visual appearance.
An analysis of sleep patterns and melatonin concentrations in a cohort of male participants exposed to varying luminance levels commonly experienced in the evening showed that melanopic irradiance is a meaningful target for efforts to limit the impact of evening display light on the time to fall asleep, melatonin and alertness.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Psychiatric Hospital of the University of Basel, Centre for Chronobiology, Basel, Switzerland (GRID:grid.412556.1) (ISNI:0000 0004 0479 0775); University of Basel, Research Platform Molecular and Cognitive Neurosciences (MCN), Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642)
2 University of Manchester, Centre for Biological Timing, Division of Neuroscience, School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
3 Max Planck Institute for Biological Cybernetics, Translational Sensory & Circadian Neuroscience, Tübingen, Germany (GRID:grid.419501.8) (ISNI:0000 0001 2183 0052); Technical University of Munich, Chronobiology & Health, TUM Department of Sport and Health Sciences (TUM SG), Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966); Technical University of Munich, TUM Institute for Advanced Study (TUM-IAS), Garching, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
4 Psychiatric Hospital of the University of Basel, Clinical Sleep Laboratory, Basel, Switzerland (GRID:grid.412556.1) (ISNI:0000 0004 0479 0775)